Tags

Type your tag names separated by a space and hit enter

Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease.
Biochem Pharmacol 2013; 85(9):1306-16BP

Abstract

Inflammatory bowel disease (IBD) is an incurable disease which affects millions of people in industrialized countries. Anecdotal and scientific evidence suggests that Cannabis use may have a positive impact in IBD patients. Here, we investigated the effect of cannabigerol (CBG), a non-psychotropic Cannabis-derived cannabinoid, in a murine model of colitis. Colitis was induced in mice by intracolonic administration of dinitrobenzene sulphonic acid (DNBS). Inflammation was assessed by evaluating inflammatory markers/parameters (colon weight/colon length ratio and myeloperoxidase activity), by histological analysis and immunohistochemistry; interleukin-1β, interleukin-10 and interferon-γ levels by ELISA, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) by western blot and RT-PCR; CuZn-superoxide dismutase (SOD) activity by a colorimetric assay. Murine macrophages and intestinal epithelial cells were used to evaluate the effect of CBG on nitric oxide production and oxidative stress, respectively. CBG reduced colon weight/colon length ratio, myeloperoxidase activity, and iNOS expression, increased SOD activity and normalized interleukin-1β, interleukin-10 and interferon-γ changes associated to DNBS administration. In macrophages, CBG reduced nitric oxide production and iNOS protein (but not mRNA) expression. Rimonabant (a CB1 receptor antagonist) did not change the effect of CBG on nitric oxide production, while SR144528 (a CB2 receptor antagonist) further increased the inhibitory effect of CBG on nitric oxide production. In conclusion, CBG attenuated murine colitis, reduced nitric oxide production in macrophages (effect being modulated by the CB2 receptor) and reduced ROS formation in intestinal epithelial cells. CBG could be considered for clinical experimentation in IBD patients.

Authors+Show Affiliations

Department of Pharmacy, University of Naples Federico II, via D Montesano 49, 80131 Naples, Italy. franborr@unina.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

23415610

Citation

Borrelli, Francesca, et al. "Beneficial Effect of the Non-psychotropic Plant Cannabinoid Cannabigerol On Experimental Inflammatory Bowel Disease." Biochemical Pharmacology, vol. 85, no. 9, 2013, pp. 1306-16.
Borrelli F, Fasolino I, Romano B, et al. Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochem Pharmacol. 2013;85(9):1306-16.
Borrelli, F., Fasolino, I., Romano, B., Capasso, R., Maiello, F., Coppola, D., ... Izzo, A. A. (2013). Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. Biochemical Pharmacology, 85(9), pp. 1306-16. doi:10.1016/j.bcp.2013.01.017.
Borrelli F, et al. Beneficial Effect of the Non-psychotropic Plant Cannabinoid Cannabigerol On Experimental Inflammatory Bowel Disease. Biochem Pharmacol. 2013 May 1;85(9):1306-16. PubMed PMID: 23415610.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Beneficial effect of the non-psychotropic plant cannabinoid cannabigerol on experimental inflammatory bowel disease. AU - Borrelli,Francesca, AU - Fasolino,Ines, AU - Romano,Barbara, AU - Capasso,Raffaele, AU - Maiello,Francesco, AU - Coppola,Diana, AU - Orlando,Pierangelo, AU - Battista,Giovanni, AU - Pagano,Ester, AU - Di Marzo,Vincenzo, AU - Izzo,Angelo A, Y1 - 2013/02/12/ PY - 2012/12/10/received PY - 2013/01/22/revised PY - 2013/01/22/accepted PY - 2013/2/19/entrez PY - 2013/2/19/pubmed PY - 2013/5/23/medline SP - 1306 EP - 16 JF - Biochemical pharmacology JO - Biochem. Pharmacol. VL - 85 IS - 9 N2 - Inflammatory bowel disease (IBD) is an incurable disease which affects millions of people in industrialized countries. Anecdotal and scientific evidence suggests that Cannabis use may have a positive impact in IBD patients. Here, we investigated the effect of cannabigerol (CBG), a non-psychotropic Cannabis-derived cannabinoid, in a murine model of colitis. Colitis was induced in mice by intracolonic administration of dinitrobenzene sulphonic acid (DNBS). Inflammation was assessed by evaluating inflammatory markers/parameters (colon weight/colon length ratio and myeloperoxidase activity), by histological analysis and immunohistochemistry; interleukin-1β, interleukin-10 and interferon-γ levels by ELISA, inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) by western blot and RT-PCR; CuZn-superoxide dismutase (SOD) activity by a colorimetric assay. Murine macrophages and intestinal epithelial cells were used to evaluate the effect of CBG on nitric oxide production and oxidative stress, respectively. CBG reduced colon weight/colon length ratio, myeloperoxidase activity, and iNOS expression, increased SOD activity and normalized interleukin-1β, interleukin-10 and interferon-γ changes associated to DNBS administration. In macrophages, CBG reduced nitric oxide production and iNOS protein (but not mRNA) expression. Rimonabant (a CB1 receptor antagonist) did not change the effect of CBG on nitric oxide production, while SR144528 (a CB2 receptor antagonist) further increased the inhibitory effect of CBG on nitric oxide production. In conclusion, CBG attenuated murine colitis, reduced nitric oxide production in macrophages (effect being modulated by the CB2 receptor) and reduced ROS formation in intestinal epithelial cells. CBG could be considered for clinical experimentation in IBD patients. SN - 1873-2968 UR - https://www.unboundmedicine.com/medline/citation/23415610/Beneficial_effect_of_the_non_psychotropic_plant_cannabinoid_cannabigerol_on_experimental_inflammatory_bowel_disease_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0006-2952(13)00054-3 DB - PRIME DP - Unbound Medicine ER -